Alerts will be sent to your verified email
Verify Email
PARMAX
|
Parmax Pharma
|
Cian Healthcare
|
Unjha Formulations
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-1624.87 % | -2.49 % | 10.34 % |
|
5yr average Equity Multiplier
|
46.04 | 2.79 | 1.62 |
|
5yr Average Asset Turnover Ratio
|
0.95 | 0.42 | 3.51 |
|
5yr Avg Net Profit Margin
|
-9.48 % | -2.06 % | 1.88 % |
|
Price to Book
|
0.0 | 0.0 | 3.5 |
|
P/E
|
0.0 | 48.65 | 116.26 |
|
5yr Avg Cash Conversion Cycle
|
-161.05 Days | -692.15 Days | 18.8 Days |
|
Inventory Days
|
73.65 Days | 163.23 Days | 28.57 Days |
|
Days Receivable
|
40.27 Days | 131.14 Days | 41.04 Days |
|
Days Payable
|
328.05 Days | 473.59 Days | 53.92 Days |
|
5yr Average Interest Coverage Ratio
|
1.16 | 0.8 | 17.56 |
|
5yr Avg ROCE
|
-9.94 % | 5.59 % | 19.44 % |
|
5yr Avg Operating Profit Margin
|
3.93 % | 14.07 % | 3.19 % |
|
5 yr average Debt to Equity
|
17.42 | 1.12 | 0.0 |
|
5yr CAGR Net Profit
|
n/a | n/a | 32.6 % |
|
5yr Average Return on Assets
|
-6.43 % | -0.86 % | 6.62 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
30.8 % | 27.1 % | 36.92 % |
|
Share Pledged by Promoters
|
0.0 | 34.48 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -43.79 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Parmax Pharma
|
Cian Healthcare
|
Unjha Formulations
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|